Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150773 | 0.85 | ITGB3 (0.47) | ITGB3ITGA2BEGLN1EGLN3LMNA | |
| SCHEMBL21151877 | 0.84 | KMT2A (0.48) | LMNATACR1NPC1RAB9A | |
| SCHEMBL24974538 | 0.79 | SLC6A9 (0.44) | ITGB3ITGA2BLMNASLC6A9 | |
| SCHEMBL19534281 | 0.77 | GPR119 (0.51) | ITGB3ITGA2BPOLBTACR1GPR119 | |
| SCHEMBL24974652 | 0.75 | MT-CO2 (0.42) | LMNAPOLBMAPTGPR119NPC1 | |
| SCHEMBL21150756 | 0.74 | GPR119 (0.37) | LMNAMAPTGPR119NPC1 | |
| SCHEMBL21151787 | 0.73 | USP30 (0.54) | ITGB3ITGA2BTACR1GPR119USP30 | |
| SCHEMBL22256978 | 0.70 | POLB (0.50) | ITGB3ITGA2BEGLN1EGLN3LMNA | |
| SCHEMBL23288897 | 0.70 | ITGB3 (0.46) | ITGB3ITGA2BPOLBTACR1GPR119 | |
| SCHEMBL19534078 | 0.69 | POLB (0.54) | ITGB3ITGA2BEGLN1EGLN3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | ITGB3 77/4885ITGA2B 35/4885EGLN1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.